Format

Send to

Choose Destination
Pharmacol Res. 2018 Feb;128:359-365. doi: 10.1016/j.phrs.2017.10.008. Epub 2017 Oct 18.

Apigenin as neuroprotective agent: Of mice and men.

Author information

1
Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran 14359-16471, Iran.
2
Depatment of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan. Electronic address: hkdr2006@gmail.com.
3
Gerontology-Geriatric Research Laboratory, Department of Medical Sciences, I.R.C.C.S. "Casa Sollievo della Sofferenza", Foggia, Italy.
4
Department of Molecular Biology, Institute 'Ruđer Bošković', Zagreb, Croatia.
5
Department of Pharmacology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
6
Department of Pharmacology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
7
Department of Physiology, Faculty of Pharmacy, University of Seville, Seville, Spain.
8
Pharmacognosy Research Laboratories & Herbal Analysis Services UK, University of Greenwich, Chatham-Maritime, Kent ME4 4TB, UK.
9
Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Santiago de Compostela 15782, Spain; Instituto de Investigación en Innovación en Salud, Facultad de Ciencias de la Salud, Universidad Central de Chile, Santiago, Chile.

Abstract

Neurodegenerative disorders (NDDs) such as Alzheimer's and Parkinson's diseases are the most common age-related pathologies that affect millions of people all over the world. To date, effective therapy for NDDs is not available and current approaches to disease management include neuroprotection strategy with a hope of maintaining and enhancing the function of survising neurons. Of course, such an approach by its own will not offer a cure but is likely to delay the disease progression by ameliorating the increase of neurotoxic agents such reactive oxygen species (ROS) as well as the associated inflammatory cascades. In this regard, natural products including flavonods that offer neuroprotection through multiple mechanisms have gained a lot of interest in recent years. In this communication, evidences from the various experimental models and clinical trials on the therapeutic potential of one promising flavonod, apigenin, is presented. Its chemistry, mechanism of action and potential benefits in the various examples of NDDs are discussed in the light of drug discovery aspects.

KEYWORDS:

Alzheimer’s disease; Apigenin; Flavonoids; Neuroprotection; Parkinson’s disease

PMID:
29055745
DOI:
10.1016/j.phrs.2017.10.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center